Celgene Corp. (CELG)

110.00
NASDAQ : Health Technology
Prev Close 109.57
Day Low/High 109.40 / 110.47
52 Wk Low/High 58.59 / 109.75
Avg Volume 3.66M
Exchange NASDAQ
Shares Outstanding 711.71M
Market Cap 77.98B
EPS 5.70
P/E Ratio 13.49
Div & Yield N.A. (N.A)

Latest News

FDA Approves REBLOZYL® (luspatercept-aamt) For The Treatment Of Anemia In Adults With Beta Thalassemia Who Require Regular Red Blood Cell Transfusions

FDA Approves REBLOZYL® (luspatercept-aamt) For The Treatment Of Anemia In Adults With Beta Thalassemia Who Require Regular Red Blood Cell Transfusions

Celgene Corporation (NASDAQ: CELG) and Acceleron Pharma Inc. (NASDAQ: XLRN) today announced the U.

Celgene To Present New And Updated Data On Key Hematology Pipeline Therapies At American Society Of Hematology (ASH) 2019 Annual Meeting

Celgene To Present New And Updated Data On Key Hematology Pipeline Therapies At American Society Of Hematology (ASH) 2019 Annual Meeting

Celgene Corporation (NASDAQ: CELG) today announced data from nearly 70 Company-sponsored, global alliance and investigator-initiated clinical studies evaluating Celgene's investigational and approved therapies will be presented at the 61st American...

Real Money Post Industrial Average Exits October on Top

Real Money Post Industrial Average Exits October on Top

The RMPIA's 3.8% jump even beat the Nasdaq Composite Index's 3.7% October climb.

Celgene Slips on Post-Earnings Analyst Downgrade

Celgene Slips on Post-Earnings Analyst Downgrade

Shares of pharmaceutical giant Celgene slip after receiving a downgrade from analysts at Baird, despite posting better-than-expected quarterly results.

Celgene Reports Third Quarter 2019 Operating And Financial Results

Celgene Reports Third Quarter 2019 Operating And Financial Results

Celgene Corporation (NASDAQ: CELG) reported third quarter 2019 total revenue of $4,520 million, a 16 percent increase compared to $3,892 million in the third quarter of 2018.

Apple, Facebook, China Trade, Fed, Nationals - 5 Things You Must Know Thursday

Apple, Facebook, China Trade, Fed, Nationals - 5 Things You Must Know Thursday

U.S. stock futures are falling following a report that said Chinese officials have doubts about reaching a comprehensive long-term trade agreement with the United States; Apple and Facebook rise after posting better-than-expected earnings; Fiat Chrysler confirms it agreed to merger with France's Peugeot.

Make Fed Day a Time for Paper Trades

Make Fed Day a Time for Paper Trades

Traders can learn from watching, as well as doing, and with the FOMC meeting landing, now's best time to practice the former.

Jim Cramer: Drug Stocks Are Too Cheap

Jim Cramer: Drug Stocks Are Too Cheap

These stocks are priced for total imperfection. That's just what you want.

Jim Cramer: Demand Is Driving This Market to All-Time Highs

Jim Cramer: Demand Is Driving This Market to All-Time Highs

The stocks of many companies anticipated a more stringent series of tariffs and we didn't get them.

Big Biotech Receives Some Needed Shots in the Arm

Big Biotech Receives Some Needed Shots in the Arm

Biogen, Novartis and Bristol-Myers Squibb are among the drugmakers that gave investors reasons for cheer on Tuesday.

Jim Cramer: The Soundness of My Methods

Jim Cramer: The Soundness of My Methods

A little bit of luck and a lot of homework can go a long way to make Big Money out of Mad Money. It's buying a Biogen, a Centene, or a Bristol-Myers that could do just that for you.

6 Top Biopharmaceutical Stock Picks You Should Know About

6 Top Biopharmaceutical Stock Picks You Should Know About

The aging population is creating a massive tailwind for companies that provide cutting-edge health care.

Celgene And The Multiple Sclerosis Association Of America Take The MS MindShift Initiative And "Brain Bulb" Hot Air Balloon To The Sky At Owl-O-Ween Festival To Educate On Multiple Sclerosis And Brain Health

Celgene And The Multiple Sclerosis Association Of America Take The MS MindShift Initiative And "Brain Bulb" Hot Air Balloon To The Sky At Owl-O-Ween Festival To Educate On Multiple Sclerosis And Brain Health

The MS MindShift: A New View of MS initiative from Celgene Corporation (NASDAQ: CELG) and the Multiple Sclerosis Association of America (MSAA) is making its third stop at the Owl-O-Ween Hot Air Balloon Festival in Kennesaw, Ga.

Raytheon, United Technologies, Yeti: 'Mad Money' Lightning Round

Raytheon, United Technologies, Yeti: 'Mad Money' Lightning Round

Jim Cramer weighs in on Raytheon, United Technologies, Yeti, Bristol-Myers Squibb, Mosaic, Square, JBG Smith Properties, Encana, BP, Waste Management.

Don't Wait for China: Cramer's 'Mad Money' Recap (Friday 9/20/19)

Don't Wait for China: Cramer's 'Mad Money' Recap (Friday 9/20/19)

Jim Cramer says it's going to take longer than most people think to reach a trade deal with China. He's got your game plan for next week.

Celgene Corporation Names Second Round Of Celgene Cancer Care Links™ Program Grant Recipients

Celgene Corporation Names Second Round Of Celgene Cancer Care Links™ Program Grant Recipients

Celgene Corporation (NASDAQ: CELG) today announced an additional ten programs selected for funding under its Celgene Cancer Care Links™ program, an initiative designed to support healthcare capacity building in resource-constrained countries around the...

Celgene Announces Phase 3 QUAZAR® AML-001 Study Of CC-486 As Maintenance Therapy In Patients With Newly Diagnosed Acute Myeloid Leukemia Met Primary And Key Secondary Endpoints

Celgene Announces Phase 3 QUAZAR® AML-001 Study Of CC-486 As Maintenance Therapy In Patients With Newly Diagnosed Acute Myeloid Leukemia Met Primary And Key Secondary Endpoints

Celgene Corporation (NASDAQ: CELG) today announced top-line results from the international phase 3, randomized, double-blind, placebo-controlled study, QUAZAR AML-001.

Jim Cramer: How to Survive This Violent Rotation

Jim Cramer: How to Survive This Violent Rotation

Emotions and panic must be checked at the door, if you are going to be a successful investor, especially right now.

Data From Ozanimod Clinical Development Program In Relapsing Forms Of Multiple Sclerosis To Be Presented At The 35th Congress Of The European Committee For Treatment And Research In Multiple Sclerosis

Data From Ozanimod Clinical Development Program In Relapsing Forms Of Multiple Sclerosis To Be Presented At The 35th Congress Of The European Committee For Treatment And Research In Multiple Sclerosis

Celgene Corporation (NASDAQ:CELG) today announced it will present 13 scientific abstracts, including new analyses from the Phase 3 ozanimod clinical development program in adults with relapsing forms of multiple sclerosis (RMS), at the 35 th Congress of...

Stocks End Higher After Trump Says China Wants to Make a Deal 'Very Badly'

Stocks End Higher After Trump Says China Wants to Make a Deal 'Very Badly'

Stocks finished higher Monday after President Donald Trump claims China contacted U.S. trade officials and said 'let's get back to' the negotiating table.

Jim Cramer: Why It Doesn't Matter How Much Amgen Paid for Otzela

Jim Cramer: Why It Doesn't Matter How Much Amgen Paid for Otzela

Jim Cramer breaks down Amgen's deal to buy Otezla's rights from Celgene.

Otezla Price Under Microscope -- but Look Closely and It Checks Out

Otezla Price Under Microscope -- but Look Closely and It Checks Out

Sure, Celgene, in its tie-up with Bristol-Myers Squibb, had to sell to meet merger requirements, but look at the future pay off for Amgen.

Alexion Shares Decline in Wake of Amgen's Deal for Otezla

Alexion Shares Decline in Wake of Amgen's Deal for Otezla

Recent speculation that the biotech giant would buy Alexion had boosted ALXN's shares. But Amgen just agreed to lay out $13.4 billion for Celgene's psoriasis drug.

M&A Appetite in Pharma Has Proved Potent: Chart of the Day

M&A Appetite in Pharma Has Proved Potent: Chart of the Day

With total deals trending toward hundreds of billions, investors may be eager to bet on who's next to be acquired.

Jim Cramer Weighs In on Amgen's Deal, Salesforce and U.S.-China Trade War

Jim Cramer Weighs In on Amgen's Deal, Salesforce and U.S.-China Trade War

Jim Cramer's breaking down his thoughts on pajama trading, and the U.S.-China trade war.

Amgen Charts Indicate Shares Want to Work Their Way Higher Longer Term

Amgen Charts Indicate Shares Want to Work Their Way Higher Longer Term

Amgen's deal to buy Otezla from Celgene should not deter the drugmaker's stock from gaining ground over the long haul.

Put the Pajamas Away: Jim Cramer on U.S.-China Trade and Amgen

Put the Pajamas Away: Jim Cramer on U.S.-China Trade and Amgen

Jim Cramer weighs in on the U.S.-China trade war and Amgen.

Amgen Adds Celgene's Otezla to Bolster Pipeline at Pricey Valuation

Amgen Adds Celgene's Otezla to Bolster Pipeline at Pricey Valuation

Amgen is finally making an expected splash out of its cash pile, but questions are abounding about the cost paid for Celgene's Otezla.

TheStreet Quant Rating: C+ (Hold)